C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines.
TL;DR: Estimation of the general stress response of breast cell lines derived from basal-like and luminal epithelium after treatment with doxorubicin or 5-fluorouracil showed that each cell type has a distinct response.
Journal ArticleDOI
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
Antoni Picornell,Isabel Echavarria,Enrique Alvarez,Sara López-Tarruella,Yolanda Jerez,Katherine A. Hoadley,Joel S. Parker,M. del Monte-Millán,Rocío Ramos-Medina,Javier Gayarre,Inmaculada Ocaña,Maria Cebollero,Tatiana Massarrah,Fernando Salvador Moreno,J. A. Garcia Saenz,H. Gomez Moreno,Ana Isabel Ballesteros,M. Ruiz Borrego,Charles M. Perou,M. Martin +19 more
TL;DR: In this analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis.
Journal ArticleDOI
Entinostat induces antitumor immune responses through immune editing of tumor neoantigens
Andrew S. Truong,Mi Zhou,Bhavani Krishnan,Takanobu Utsumi,Ujjawal Manocha,Kyle G. Stewart,Wolfgang Beck,Tracy L. Rose,Matthew I. Milowsky,Xiaping He,Christof C. Smith,Lisa M. Bixby,Charles M. Perou,Sara E. Wobker,Sean T. Bailey,Benjamin G. Vincent,William Y. Kim +16 more
TL;DR: In this article, entinostat selectively promoted immune editing of tumor neoantigens, effectively remodeling the tumor immune microenvironment, resulting in a robust antitumor response that was cell autonomous, dependent upon antigen presentation.
Journal ArticleDOI
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Jonathan Shepherd,Karla V. Ballman,Mei Yin C. Polley,J. Campbell,Cheng Fan,Sara R. Selitsky,Aranzazu Fernandez-Martinez,Joel S. Parker,Katherine A. Hoadley,Zhiyuan Hu,Yan Li,Matthew G. Soloway,Patricia A. Spears,Baljit Singh,Sara M. Tolaney,George Somlo,Elisa Port,Cynthia X. Ma,Charles S. Kuzma,Eleftherios P. Mamounas,Mehra Golshan,Jennifer R. Bellon,Deborah Collyar,Olwen Hahn,Clifford A. Hudis,Eric P. Winer,Ann H. Partridge,Terry Hyslop,Lisa A. Carey,Charles M. Perou,William M. Sikov +30 more
TL;DR: Despite higher pCR rates, neither carboplatin nor bevacizumab appeared to improve LTOs although the study was not powered to assess these secondary end points.